Journal article
Finasteride for benign prostatic hyperplasia
American family physician, v 46(5), pp 1511-1514
01 Nov 1992
PMID: 1279965
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The pathogenesis of benign prostatic hyperplasia is related to the action of 5 alpha-dihydrotestosterone (DHT), the physiologically active form of testosterone. The conversion of testosterone to DHT is catalyzed intracellularly in prostatic tissue by the enzyme 5 alpha-reductase. Finasteride blocks the action of 5 alpha-reductase by competitively inhibiting the binding of testosterone to 5 alpha-reductase. The maximum effect of finasteride on reducing prostatic volume occurs after three months of oral therapy. Most patients experience improvement in urine flow rates, and side effects are minimal. However, following discontinuation of treatment, serum DHT levels return to baseline within two weeks.
Metrics
12 Record Views
Details
- Title
- Finasteride for benign prostatic hyperplasia
- Creators
- S HasinskiJ L MillerL I Rose
- Publication Details
- American family physician, v 46(5), pp 1511-1514
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Management
- Web of Science ID
- WOS:A1992JY22900015
- Scopus ID
- 2-s2.0-0026468587
- Other Identifier
- 991019184180204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Primary Health Care